RAMM Pharma Announces Approval and Registration of Epifractán™ 2% by Peru’s Ministry of Health
July 16, 2020 08:00 ET
|
RAMM Pharma Corp.
TORONTO, July 16, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Announces Approval and Registration of Epifractán™ 5% by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru
July 09, 2020 07:59 ET
|
RAMM Pharma Corp.
TORONTO, July 09, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma announces its quarter financial results for Q2 2020
June 29, 2020 17:01 ET
|
RAMM Pharma Corp.
TORONTO, June 29, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid
April 15, 2020 11:55 ET
|
RAMM Pharma Corp.
TORONTO, April 15, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), announces its intention to commence a normal course...
RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements
March 30, 2020 09:36 ET
|
RAMM Pharma Corp.
TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution
March 26, 2020 14:01 ET
|
RAMM Pharma Corp.
TORONTO, March 26, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update
March 23, 2020 15:06 ET
|
RAMM Pharma Corp.
TORONTO, March 23, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. to Acquire NettaLife, a Leading Developer of Cannabis-Based Products for Pets and Large Animals
February 25, 2020 07:30 ET
|
RAMM Pharma Corp.
TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Welcomes Legalization of Medical Cannabis in Brazil
December 05, 2019 09:23 ET
|
RAMM Pharma Corp.
TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Corp. Commences Trading on the Canadian Securities Exchange Under Ticker Symbol “RAMM” and Provides Corporate Update
November 08, 2019 08:24 ET
|
RAMM Pharma Corp.
TORONTO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...